These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33844095)

  • 1. Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans.
    Fülöp GÁ; Oláh A; Csipo T; Kovács Á; Pórszász R; Veress R; Horváth B; Nagy L; Bódi B; Fagyas M; Helgadottir SL; Bánhegyi V; Juhász B; Bombicz M; Priksz D; Nanasi P; Merkely B; Édes I; Csanádi Z; Papp Z; Radovits T; Tóth A
    Basic Res Cardiol; 2021 Apr; 116(1):24. PubMed ID: 33844095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes.
    Horváth B; Szentandrássy N; Veress R; Almássy J; Magyar J; Bányász T; Tóth A; Papp Z; Nánási PP
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Dec; 390(12):1239-1246. PubMed ID: 28940010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analyses of the inotropic compound omecamtiv mecarbil in rat and human cardiac preparations.
    Rhoden A; Schulze T; Pietsch N; Christ T; Hansen A; Eschenhagen T
    Am J Physiol Heart Circ Physiol; 2022 Mar; 322(3):H373-H385. PubMed ID: 35030072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity.
    Bakkehaug JP; Kildal AB; Engstad ET; Boardman N; Næsheim T; Rønning L; Aasum E; Larsen TS; Myrmel T; How OJ
    Circ Heart Fail; 2015 Jul; 8(4):766-75. PubMed ID: 26025342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of omecamtiv mecarbil on calcium-transients and contractility in a translational canine myocyte model.
    Gao B; Sutherland W; Vargas HM; Qu Y
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00656. PubMed ID: 32969560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of late Na+ current, a novel target to improve diastolic function and electrical abnormalities in Dahl salt-sensitive rats.
    Chi L; Belardinelli L; Zeng A; Hirakawa R; Rajamani S; Ling H; Dhalla AK
    Am J Physiol Heart Circ Physiol; 2016 May; 310(10):H1313-20. PubMed ID: 26993228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amrinone enhances myocardial contractility and improves left ventricular diastolic function in conscious and anesthetized chronically instrumented dogs.
    Pagel PS; Hettrick DA; Warltier DC
    Anesthesiology; 1993 Oct; 79(4):753-65. PubMed ID: 8214755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omecamtiv mecarbil augments cardiomyocyte contractile activity both at resting and systolic Ca
    Ráduly AP; Tóth A; Sárkány F; Horváth B; Szentandrássy N; Nánási PP; Csanádi Z; Édes I; Papp Z; Borbély A
    ESC Heart Fail; 2023 Apr; 10(2):1326-1335. PubMed ID: 36722665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium.
    Mamidi R; Li J; Gresham KS; Verma S; Doh CY; Li A; Lal S; Dos Remedios CG; Stelzer JE
    Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29030372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The energy-saving effect of a new myosin activator, omecamtiv mecarbil, on LV mechanoenergetics in rat hearts with blood-perfused isovolumic contraction model.
    Obata K; Morita H; Takaki M
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Sep; 392(9):1065-1070. PubMed ID: 31267148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omecamtiv mecarbil attenuates length-tension relationship in healthy rat myocardium and preserves it in monocrotaline-induced pulmonary heart failure.
    Lookin O; Kuznetsov D; Protsenko Y
    Clin Exp Pharmacol Physiol; 2022 Jan; 49(1):84-93. PubMed ID: 34459025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.
    Teerlink JR; Clarke CP; Saikali KG; Lee JH; Chen MM; Escandon RD; Elliott L; Bee R; Habibzadeh MR; Goldman JH; Schiller NB; Malik FI; Wolff AA
    Lancet; 2011 Aug; 378(9792):667-75. PubMed ID: 21856480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omecamtiv mecarbil treatment improves post-resuscitation cardiac function and neurological outcome in a rat model.
    Wu SN; Tsai MS; Huang CH; Chen WJ
    PLoS One; 2022; 17(2):e0264165. PubMed ID: 35176110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (-)-noradrenaline.
    Dashwood A; Cheesman E; Wong YW; Haqqani H; Beard N; Hay K; Spratt M; Chan W; Molenaar P
    Pharmacol Res Perspect; 2021 May; 9(3):e00760. PubMed ID: 33929079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a myofilament calcium sensitizer on left ventricular systolic and diastolic function in rats with volume overload heart failure.
    Wilson K; Guggilam A; West TA; Zhang X; Trask AJ; Cismowski MJ; de Tombe P; Sadayappan S; Lucchesi PA
    Am J Physiol Heart Circ Physiol; 2014 Dec; 307(11):H1605-17. PubMed ID: 25260618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.
    Teerlink JR; Felker GM; McMurray JJV; Ponikowski P; Metra M; Filippatos GS; Ezekowitz JA; Dickstein K; Cleland JGF; Kim JB; Lei L; Knusel B; Wolff AA; Malik FI; Wasserman SM;
    J Am Coll Cardiol; 2016 Mar; 67(12):1444-1455. PubMed ID: 27012405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.
    Cleland JG; Teerlink JR; Senior R; Nifontov EM; Mc Murray JJ; Lang CC; Tsyrlin VA; Greenberg BH; Mayet J; Francis DP; Shaburishvili T; Monaghan M; Saltzberg M; Neyses L; Wasserman SM; Lee JH; Saikali KG; Clarke CP; Goldman JH; Wolff AA; Malik FI
    Lancet; 2011 Aug; 378(9792):676-83. PubMed ID: 21856481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive in vitro pro-arrhythmic assays demonstrate that omecamtiv mecarbil has low pro-arrhythmic risk.
    Qu Y; Gao B; Arimura Z; Fang M; Vargas HM
    Clin Transl Sci; 2021 Jul; 14(4):1600-1610. PubMed ID: 33955165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Therapy With Dobutamine and Omecamtiv Mecarbil in Pigs With Ischemic Acute Heart Failure Is Attributed to the Effect of Dobutamine.
    Rødland L; Rønning L; Kildal AB; Myrmel T; How OJ
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):232-239. PubMed ID: 31645117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term levosimendan treatment improves systolic function and myocardial relaxation in mice with cardiomyocyte-specific disruption of the Serca2 gene.
    Hillestad V; Kramer F; Golz S; Knorr A; Andersson KB; Christensen G
    J Appl Physiol (1985); 2013 Nov; 115(10):1572-80. PubMed ID: 24072410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.